Skip to main content
SpringerLink
Log in

Clinical Activity of Metronomic Chemotherapy in Central Nervous System Cancers

  • Chapter
  • First Online:
Book cover Metronomic Chemotherapy

  • 700 Accesses

Abstract

Despite recent advances glioblastoma (GBM), which is the most frequent malignant central nervous system (CNS) tumor, remains a lethal disease. One of characteristics in malignant gliomas is the robust and aberrant vasculature within the tumor which could be the target for the frequent administration of low-dose metronomic chemotherapy. This chapter will mainly focus on determining current status and recent trends of metronomic treatment for CNS tumor by review of published literatures. Indeed, many preclinical evidences support the metronomic use of camptothecins and temozolomide in glioblastoma models and numerous clinical applications of metronomic regimens (e.g. etoposide, temozolomide) for adult patients with tumors of CNS have been described. Moreover, metronomic treatment may serve as a useful platform for combination strategies in certain CNS tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996

    Article  CAS  PubMed  Google Scholar 

  2. Browder T et al (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60(7):1878–1886

    CAS  PubMed  Google Scholar 

  3. Vredenburgh JJ et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253–1259

    Article  CAS  PubMed  Google Scholar 

  4. Vredenburgh JJ et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722–4729

    Article  CAS  PubMed  Google Scholar 

  5. Klement G et al (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105(8):R15–R24

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Samuel DP, Wen PY, Kieran MW (2009) Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. Expert Opin Investig Drugs 18(7):973–983

    Article  CAS  PubMed  Google Scholar 

  7. Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4(6):423–436

    Article  CAS  PubMed  Google Scholar 

  8. Chen C et al (2013) The efficacy of temozolomide for recurrent glioblastoma multiforme. Eur J Neurol 20(2):223–230

    Article  CAS  PubMed  Google Scholar 

  9. Pegg AE (2000) Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res 462(2–3):83–100

    Article  CAS  PubMed  Google Scholar 

  10. Hegi ME et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003

    Article  CAS  PubMed  Google Scholar 

  11. Pegg AE, Dolan ME, Moschel RC (1995) Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 51:167–223

    Article  CAS  PubMed  Google Scholar 

  12. Bello L et al (2001) Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 61(20):7501–7506

    CAS  PubMed  Google Scholar 

  13. Takano S et al (2010) Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth. J Neurooncol 99(2):177–185

    Article  CAS  PubMed  Google Scholar 

  14. Ma L et al (2005) In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer Res 65(12):5365–5373

    Article  CAS  PubMed  Google Scholar 

  15. Clements MK et al (1999) Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother Pharmacol 44(5):411–416

    Article  CAS  PubMed  Google Scholar 

  16. Kurzen H et al (2003) Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs 14(7):515–522

    Article  CAS  PubMed  Google Scholar 

  17. Kim JT et al (2006) Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep 16(1):33–39

    PubMed  Google Scholar 

  18. Chamberlain MC (1995) Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide. Arch Neurol 52(5):509–513

    Article  CAS  PubMed  Google Scholar 

  19. Fulton D, Urtasun R, Forsyth P (1996) Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J Neurooncol 27(2):149–155

    Article  CAS  PubMed  Google Scholar 

  20. Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105(8):1045–1047

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Kesari S et al (2007) Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol 9(3):354–363

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Reardon DA et al (2009) Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer 101(12):1986–1994

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Tolcher AW et al (2003) Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88(7):1004–1011

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Kong DS et al (2010) Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol 12(3):289–296

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Brandes AA et al (2006) Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 95(9):1155–1160

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Perry JR et al (2010) Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28(12):2051–2057

    Article  CAS  PubMed  Google Scholar 

  27. Omuro A et al (2013) Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol 15(2):242–250

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Kong DS et al (2006) A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep 16(5):1117–1121

    CAS  PubMed  Google Scholar 

  29. Stockhammer F et al (2010) Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma. J Neurooncol 100(3):407–415

    Article  CAS  PubMed  Google Scholar 

  30. Brada M et al (2010) Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol 28(30):4601–4608

    Article  CAS  PubMed  Google Scholar 

  31. Lien K et al (2013) Low-dose metronomic chemotherapy: A systematic literature analysis. Eur J Cancer 49(16):3387–3395

    Article  CAS  PubMed  Google Scholar 

  32. Chamberlain MC (2008) Pseudoprogression in glioblastoma. J Clin Oncol 26(26):4359; author reply 4359–4360

    Article  PubMed  Google Scholar 

  33. Kong DS et al (2011) Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status. AJNR Am J Neuroradiol 32(2):382–387

    Article  PubMed  Google Scholar 

  34. Brandes AA et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26(13):2192–2197

    Article  PubMed  Google Scholar 

  35. Penel N, Adenis A, Bocci G (2012) Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going? Crit Rev Oncol Hematol 82(1):40–50

    Article  PubMed  Google Scholar 

  36. Tuettenberg J et al (2005) Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol 131(1):31–40

    Article  CAS  PubMed  Google Scholar 

  37. Clarke JL et al (2009) Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol 27(23):3861–3867

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Gilbert MR et al (2013) Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial. J Clin Oncol 31(32):4085–4091

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Needle MN et al (1997) Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med Pediatr Oncol 29(1):28–32

    Article  CAS  PubMed  Google Scholar 

  40. Mulne AF et al (2000) Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 22(1):41–44

    Article  CAS  PubMed  Google Scholar 

  41. Baruchel S et al (2006) Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer 42(14):2335–2342

    Article  CAS  PubMed  Google Scholar 

  42. Peyrl A et al (2012) Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatr Blood Cancer 59(3):511–517

    Article  PubMed  Google Scholar 

  43. Robison NJ et al (2014) A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer 61(4):636–642

    Article  CAS  PubMed  Google Scholar 

  44. Sharp JR et al (2010) A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma. Eur J Cancer 46(18):3271–3279

    Article  CAS  PubMed  Google Scholar 

  45. Addeo R et al (2012) Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases. Cancer Chemother Pharmacol 70(4):603–609

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 ilwondong, Kangnam-gu, Seoul, 135-710, South Korea

    Doo-Sik Kong MD, PhD & Do-Hyun Nam MD, PhD

Authors
  1. Doo-Sik Kong MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Do-Hyun Nam MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Do-Hyun Nam MD, PhD .

Editor information

Editors and Affiliations

  1. Division of Pharmacology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

    Guido Bocci

  2. Department of Biological Sciences, University of Texas at El Paso, El Paso, Texas, USA

    Giulio Francia

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kong, DS., Nam, DH. (2014). Clinical Activity of Metronomic Chemotherapy in Central Nervous System Cancers. In: Bocci, G., Francia, G. (eds) Metronomic Chemotherapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43604-2_10

Download citation

Publish with us

Policies and ethics

Search

Navigation